Rick Admiraal1, Charlotte van Kesteren2, Cornelia M Jol-van der Zijde3, Arjan C Lankester3, Marc B Bierings4, Toine C G Egberts5, Maarten J D van Tol3, Catherijne A J Knibbe6, Robbert G M Bredius3, Jaap J Boelens7. 1. Paediatric Blood and Marrow Transplant Program, University Medical Center Utrecht, Utrecht, Netherlands; U-DANCE, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands; Department of Paediatrics, Leiden University Medical Center, Leiden, Netherlands; Department of Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, Netherlands. 2. Paediatric Blood and Marrow Transplant Program, University Medical Center Utrecht, Utrecht, Netherlands; U-DANCE, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands; Department of Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, Netherlands. 3. Department of Paediatrics, Leiden University Medical Center, Leiden, Netherlands. 4. Paediatric Blood and Marrow Transplant Program, University Medical Center Utrecht, Utrecht, Netherlands. 5. Department of Clinical Pharmacology and Pharmacoepidemiology, University Medical Center Utrecht, Utrecht, Netherlands. 6. Department of Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, Netherlands; Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, Netherlands. 7. Paediatric Blood and Marrow Transplant Program, University Medical Center Utrecht, Utrecht, Netherlands; U-DANCE, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: j.j.boelens@umcutrecht.nl.
Abstract
BACKGROUND: Anti-thymocyte globulin (ATG) was introduced into the conditioning regimen in haemopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. However, ATG can also cause delayed immune reconstitution of donor T cells. We studied the relation between exposure to active ATG and clinical outcomes in children. METHODS: In this retrospective analysis, all patients (age 0·2-23 years) receiving their first HCT between April 1, 2004, and April 1, 2012, who received ATG (thymoglobulin) in two Dutch paediatric HCT programmes were included. The cumulative dose of ATG was chosen according to local protocols and was given intravenously over 4 days consecutively. ATG exposure measures (maximum concentration, concentration at time of HCT, clearance, days to reach a concentration below the lympholytic concentration of one arbitrary unit [AU] per mL, total area under the curve [AUC], AUC before HCT, and AUC after HCT) were calculated using a validated population pharmacokinetic model. The main outcome of interest was immune reconstitution (defined as CD4+ T cells >0·05 × 10(9) cells per L in two consecutive measurements within 100 days). Other outcomes of interest were survival, acute and chronic GvHD, and graft failure. We used Cox proportional hazard models, logistic regression models, and Fine-Gray competing risk regressions for analyses. FINDINGS: 251 patients were included. The chance of successful immune reconstitution decreased as the ATG AUC after HCT increased (odds ratio 0·991, 95% CI 0·987-0·996; p<0·0001). Within the cord blood group, we noted decreased immune reconstitution above the lowest AUC quartile (≥ 20 AU × day/mL; p=0·0024), whereas in the bone marrow or peripheral blood stem cell group, decreased immune reconstitution was noted only in the highest quartile (≥ 100 AU × day/mL; p=0·0024). Successful immune reconstitution by day 100 was associated with increased overall survival (hazard ratio [HR] 0·49, 95% CI 0·29-0·81; p=0·0047) caused by reduced non-relapse mortality (0·40, 0·21-0·77; p=0·0062), and relapse-related mortality in myeloid leukaemia (0·25, 0·08-0·76; p=0·015). An AUC before transplantation of at least 40 AU × day/mL resulted in a lower incidence of acute GvHD (grade 2-4 HR 0·979, 95% CI 0·963-0·994; p=0·0081; and grade 3-4 0·975, 0·952-0·998; p=0·033), chronic GvHD (0·983, 0·968-0·998; p=0·029), and graft failure (0·981, 0·965-0·997; p=0·020) compared with an AUC of less than 40 AU × day/mL. INTERPRETATION: These results stress the importance of improving the efficacy and safety of ATG in HCT by amending dosage and timing. Individualised dosing and timing of ATG to aim for optimum exposure before and after HCT could result in improved outcomes after paediatric HCT. FUNDING: Dutch Organization for Scientific Research.
BACKGROUND: Anti-thymocyte globulin (ATG) was introduced into the conditioning regimen in haemopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. However, ATG can also cause delayed immune reconstitution of donor T cells. We studied the relation between exposure to active ATG and clinical outcomes in children. METHODS: In this retrospective analysis, all patients (age 0·2-23 years) receiving their first HCT between April 1, 2004, and April 1, 2012, who received ATG (thymoglobulin) in two Dutch paediatric HCT programmes were included. The cumulative dose of ATG was chosen according to local protocols and was given intravenously over 4 days consecutively. ATG exposure measures (maximum concentration, concentration at time of HCT, clearance, days to reach a concentration below the lympholytic concentration of one arbitrary unit [AU] per mL, total area under the curve [AUC], AUC before HCT, and AUC after HCT) were calculated using a validated population pharmacokinetic model. The main outcome of interest was immune reconstitution (defined as CD4+ T cells >0·05 × 10(9) cells per L in two consecutive measurements within 100 days). Other outcomes of interest were survival, acute and chronic GvHD, and graft failure. We used Cox proportional hazard models, logistic regression models, and Fine-Gray competing risk regressions for analyses. FINDINGS: 251 patients were included. The chance of successful immune reconstitution decreased as the ATG AUC after HCT increased (odds ratio 0·991, 95% CI 0·987-0·996; p<0·0001). Within the cord blood group, we noted decreased immune reconstitution above the lowest AUC quartile (≥ 20 AU × day/mL; p=0·0024), whereas in the bone marrow or peripheral blood stem cell group, decreased immune reconstitution was noted only in the highest quartile (≥ 100 AU × day/mL; p=0·0024). Successful immune reconstitution by day 100 was associated with increased overall survival (hazard ratio [HR] 0·49, 95% CI 0·29-0·81; p=0·0047) caused by reduced non-relapse mortality (0·40, 0·21-0·77; p=0·0062), and relapse-related mortality in myeloid leukaemia (0·25, 0·08-0·76; p=0·015). An AUC before transplantation of at least 40 AU × day/mL resulted in a lower incidence of acute GvHD (grade 2-4 HR 0·979, 95% CI 0·963-0·994; p=0·0081; and grade 3-4 0·975, 0·952-0·998; p=0·033), chronic GvHD (0·983, 0·968-0·998; p=0·029), and graft failure (0·981, 0·965-0·997; p=0·020) compared with an AUC of less than 40 AU × day/mL. INTERPRETATION: These results stress the importance of improving the efficacy and safety of ATG in HCT by amending dosage and timing. Individualised dosing and timing of ATG to aim for optimum exposure before and after HCT could result in improved outcomes after paediatric HCT. FUNDING: Dutch Organization for Scientific Research.
Authors: Martijn H Brugman; Anna-Sophia Wiekmeijer; Marja van Eggermond; Ingrid Wolvers-Tettero; Anton W Langerak; Edwin F E de Haas; Leonid V Bystrykh; Jon J van Rood; Gerald de Haan; Willem E Fibbe; Frank J T Staal Journal: Proc Natl Acad Sci U S A Date: 2015-10-19 Impact factor: 11.205
Authors: Rosy Dabas; Kareem Jamani; Shahbal B Kangarloo; Poonam Dharmani-Khan; Tyler S Williamson; Samar Ousia; Caylib Durand; Don Morris; Douglas Mahoney; Lynn Savoie; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Faisal M Khan; Andrew Daly; Jan Storek Journal: Blood Adv Date: 2019-05-14
Authors: Claudia Langebrake; Rick Admiraal; Erik van Maarseveen; Agnès Bonnin; Tiene Bauters Journal: Bone Marrow Transplant Date: 2019-05-17 Impact factor: 5.483
Authors: Vanessa A Fabrizio; M Irene Rodriguez-Sanchez; Audrey Mauguen; Parastoo B Dahi; Ekaterina Doubrovina; Richard J O'Reilly; Susan E Prockop Journal: Blood Adv Date: 2021-01-26
Authors: R Admiraal; R Chiesa; C A Lindemans; S Nierkens; M B Bierings; A B Versluijs; P Hiwarkar; J M Furtado Silva; P Veys; J J Boelens Journal: Bone Marrow Transplant Date: 2016-05-09 Impact factor: 5.483
Authors: Imke H Bartelink; Arief Lalmohamed; Elisabeth M L van Reij; Christopher C Dvorak; Rada M Savic; Juliette Zwaveling; Robbert G M Bredius; Antoine C G Egberts; Marc Bierings; Morris Kletzel; Peter J Shaw; Christa E Nath; George Hempel; Marc Ansari; Maja Krajinovic; Yves Théorêt; Michel Duval; Ron J Keizer; Henrique Bittencourt; Moustapha Hassan; Tayfun Güngör; Robert F Wynn; Paul Veys; Geoff D E Cuvelier; Sarah Marktel; Robert Chiesa; Morton J Cowan; Mary A Slatter; Melisa K Stricherz; Cathryn Jennissen; Janel R Long-Boyle; Jaap Jan Boelens Journal: Lancet Haematol Date: 2016-10-13 Impact factor: 18.959